Clinicopathologic features of breast cancers diagnosed in women treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort.
Hodgkin lymphoma
breast neoplasms
cancer epidemiology
radiation therapy
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 Apr 2022
01 Apr 2022
Historique:
revised:
22
11
2021
received:
20
09
2021
accepted:
23
11
2021
pubmed:
18
12
2021
medline:
7
4
2022
entrez:
17
12
2021
Statut:
ppublish
Résumé
Childhood and young adult survivors of Hodgkin lymphoma (HL) are at elevated risk of developing breast cancer, yet little data exist on the tumor characteristics that develop in this high-risk patient population. The National Cancer Institute's Surveillance, Epidemiology, and End Results database was used to identify breast cancers diagnosed between 1990 and 2016 in women who had received prior radiation therapy for HL at age 30 years or younger. Clinicopathologic features of subsequent breast cancers (breast cancer after radiation therapy for HL [BC-HL]) were examined and compared with breast cancers diagnosed in women who had no prior malignancy (breast cancer with no prior malignancy [BC-NPM]). In total, 321 breast cancers were identified in 257 women who had a history of radiation therapy for HL. The median age at HL diagnosis was 22 years (interquartile range, 18-26 years), and nearly all patients in the BC-HL group (97.9%) were diagnosed ≥8 years after radiation therapy. Overall, 56 patients in the BC-HL group (21.8%) developed bilateral breast cancer. Compared with women who had BC-NPM, those who had BC-HL were younger (43 vs 60 years; P < .001) and were less likely to present with ductal carcinoma in situ (8.4% vs 14.9%; P = .001). On multivariable analysis that included adjustment for age, invasive BC-HL was associated with smaller (≤2 cm) tumor size (odds ratio, 1.64; 95% CI, 1.25-2.15) and upper outer quadrant tumors (odds ratio, 1.37; 95% CI, 1.04-1.81) compared with BC-NPM. In a subset analysis of 102 women who had HER2/neu status available, the distribution of biologic subtype was not significantly different between BC-HL and BC-NPM (P = .16). Breast cancers in women who previously received radiation therapy for HL are characterized by earlier onset disease, although most remain estrogen receptor-positive and have early stage disease at presentation. Women who have had radiation therapy for Hodgkin lymphoma at a young age are at increased risk of developing early onset breast cancer; however, most of these breast cancers are sensitive to hormones (estrogen receptor-positive) and are diagnosed at early stages. Because these breast tumors are estrogen receptor-positive, medications that prevent breast cancer by blocking the effect of or lowering hormone levels (also termed endocrine prevention) may be useful in this group of high-risk women.
Sections du résumé
BACKGROUND
BACKGROUND
Childhood and young adult survivors of Hodgkin lymphoma (HL) are at elevated risk of developing breast cancer, yet little data exist on the tumor characteristics that develop in this high-risk patient population.
METHODS
METHODS
The National Cancer Institute's Surveillance, Epidemiology, and End Results database was used to identify breast cancers diagnosed between 1990 and 2016 in women who had received prior radiation therapy for HL at age 30 years or younger. Clinicopathologic features of subsequent breast cancers (breast cancer after radiation therapy for HL [BC-HL]) were examined and compared with breast cancers diagnosed in women who had no prior malignancy (breast cancer with no prior malignancy [BC-NPM]).
RESULTS
RESULTS
In total, 321 breast cancers were identified in 257 women who had a history of radiation therapy for HL. The median age at HL diagnosis was 22 years (interquartile range, 18-26 years), and nearly all patients in the BC-HL group (97.9%) were diagnosed ≥8 years after radiation therapy. Overall, 56 patients in the BC-HL group (21.8%) developed bilateral breast cancer. Compared with women who had BC-NPM, those who had BC-HL were younger (43 vs 60 years; P < .001) and were less likely to present with ductal carcinoma in situ (8.4% vs 14.9%; P = .001). On multivariable analysis that included adjustment for age, invasive BC-HL was associated with smaller (≤2 cm) tumor size (odds ratio, 1.64; 95% CI, 1.25-2.15) and upper outer quadrant tumors (odds ratio, 1.37; 95% CI, 1.04-1.81) compared with BC-NPM. In a subset analysis of 102 women who had HER2/neu status available, the distribution of biologic subtype was not significantly different between BC-HL and BC-NPM (P = .16).
CONCLUSIONS
CONCLUSIONS
Breast cancers in women who previously received radiation therapy for HL are characterized by earlier onset disease, although most remain estrogen receptor-positive and have early stage disease at presentation.
LAY SUMMARY
BACKGROUND
Women who have had radiation therapy for Hodgkin lymphoma at a young age are at increased risk of developing early onset breast cancer; however, most of these breast cancers are sensitive to hormones (estrogen receptor-positive) and are diagnosed at early stages. Because these breast tumors are estrogen receptor-positive, medications that prevent breast cancer by blocking the effect of or lowering hormone levels (also termed endocrine prevention) may be useful in this group of high-risk women.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1365-1372Subventions
Organisme : Fonds de Recherche du Québec - Santé
ID : 309854
Informations de copyright
© 2021 American Cancer Society.
Références
Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol. 2003;21:4386-4394. doi:10.1200/JCO.2003.11.059
Constine LS, Tarbell N, Hudson MM, et al. Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys. 2008;72:24-33. doi:10.1016/j.ijrobp.2008.04.067
Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003;290:465-475. doi:10.1001/jama.290.4.465
Henderson TO, Amsterdam A, Bhatia S, et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med. 2010;152:444-455; W144-W154. doi:10.7326/0003-4819-152-7-201004060-00009
Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402-2416. doi:10.1001/jama.2017.7112
Moskowitz CS, Chou JF, Wolden SL, et al. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol. 2014;32:2217-2223. doi:10.1200/JCO.2013.54.4601
Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group long-term follow-up guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol. 2004;22:4979-4990. doi:10.1200/JCO.2004.11.032
Ng AK, Garber JE, Diller LR, et al. Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. J Clin Oncol. 2013;31:2282-2288. doi:10.1200/JCO.2012.46.5732
Mulder RL, Hudson MM, Bhatia S, et al. Updated breast cancer surveillance recommendations for female survivors of childhood, adolescent, and young adult cancer from the International Guideline Harmonization Group. J Clin Oncol. 2020;38:4194-4207. doi:10.1200/JCO.20.00562
Boucher AA, Blaes AH. Prophylactic mastectomy: a treatment alternative for Hodgkin survivors? Clin Breast Cancer. 2013;13:307-308. doi:10.1016/j.clbc.2013.06.001
Elkin EB, Klem ML, Gonzales AM, et al. Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study. J Clin Oncol. 2011;29:2466-2473. doi:10.1200/jco.2010.32.4079
Dores GM, Anderson WF, Beane Freeman LE, Fraumeni JF Jr, Curtis RE. Risk of breast cancer according to clinicopathologic features among long-term survivors of Hodgkin's lymphoma treated with radiotherapy. Br J Cancer. 2010;103:1081-1084. doi:10.1038/sj.bjc.6605877
Veit-Rubin N, Rapiti E, Usel M, et al. Risk, characteristics, and prognosis of breast cancer after Hodgkin's lymphoma. Oncologist. 2012;17:783-791. doi:10.1634/theoncologist.2011-0451
Milano MT, Li H, Gail MH, Constine LS, Travis LB. Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: a population-based study. J Clin Oncol. 2010;28:5088-5096. doi:10.1200/JCO.2010.29.5683
Withrow DR, Morton LM, Curtis RE, Schonfeld SJ, Berrington de Gonzalez A. Association of treatment for Hodgkin lymphoma with estrogen receptor status of subsequent breast cancers. JAMA Oncol. 2018;4:414-416. doi:10.1001/jamaoncol.2017.4887
Veiga LH, Curtis RE, Morton LM, et al. Association of breast cancer risk after childhood cancer with radiation dose to the breast and anthracycline use: a report from the Childhood Cancer Survivor Study. JAMA Pediatr. 2019;173:1171-1179. doi:10.1001/jamapediatrics.2019.3807
Schaapveld M, Aleman BM, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma. N Engl J Med. 2015;373:2499-2511. doi:10.1056/NEJMoa1505949
Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2019 Submission (2000-2017) <Katrina/Rita Population Adjustment>-Linked To County Attributes-Total US, 1969-2018 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Surveillance Systems Branch; 2020.
Surveillance Research Program, National Cancer Institute. SEER*Stat Software. Version 8.3.8. Surveillance Research Program, National Cancer Institute; 2020.
Allen SD, Wallis MG, Cooke R, Swerdlow AJ. Radiologic features of breast cancer after mantle radiation therapy for Hodgkin disease: a study of 230 cases. Radiology. 2014;272:73-78. doi:10.1148/radiol.14131789
Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst. 1993;85:25-31. doi:10.1093/jnci/85.1.25
Demoor-goldschmidt C, Supiot S, Mahé MA, et al. Clinical and histological features of second breast cancers following radiotherapy for childhood and young adult malignancy. Br J Radiol. 2018;91:20170824. doi:10.1259/bjr.20170824
Hodgson DC, Koh ES, Tran TH, et al. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer. 2007;110:2576-2586. doi:10.1002/cncr.23081
Iorio GC, Salvestrini V, Borghetti P, et al. The impact of modern radiotherapy on radiation-induced late sequelae: focus on early-stage mediastinal classical Hodgkin lymphoma. A critical review by the Young Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Crit Rev Oncol Hematol. 2021;161:103326. doi:10.1016/j.critrevonc.2021.103326
Baues C, Marnitz S, Engert A, et al. Proton versus photon deep inspiration breath hold technique in patients with Hodgkin lymphoma and mediastinal radiation: a planning comparison of deep inspiration breath hold intensity modulation radiotherapy and intensity modulated proton therapy. Radiat Oncol. 2018;13:122. doi:10.1186/s13014-018-1066-2
De Bruin ML, Sparidans J, van't Veer MB, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol. 2009;27:4239-4246. doi:10.1200/JCO.2008.19.9174
Sakai T, Ozkurt E, DeSantis S, et al. National trends of synchronous bilateral breast cancer incidence in the United States. Breast Cancer Res Treat. 2019;178:161-167. doi:10.1007/s10549-019-05363-0
Boughey JC, Attai DJ, Chen SL, et al. Contralateral prophylactic mastectomy (CPM) consensus statement from the American Society of Breast Surgeons: data on CPM outcomes and risks. Ann Surg Oncol. 2016;23:3100-3105. doi:10.1245/s10434-016-5443-5
Greenfield DM, Wright J, Brown JE, et al. High incidence of late effects found in Hodgkin's lymphoma survivors, following recall for breast cancer screening. Br J Cancer. 2006;94:469-472. doi:10.1038/sj.bjc.6602974
Kwong A, Hancock SL, Bloom JR, et al. Mammographic screening in women at increased risk of breast cancer after treatment of Hodgkin's disease. Breast J. 2008;14:39-48. doi:10.1111/j.1524-4741.2007.00524.x
Lee L, Pintilie M, Hodgson DC, Goss PE, Crump M. Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin's lymphoma. Ann Oncol. 2008;19:62-67. doi:10.1093/annonc/mdm440
Lee CH, Dershaw DD, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol. 2010;7:18-27. doi:10.1016/j.jacr.2009.09.022
Sardanelli F, Boetes C, Borisch B, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010;46:1296-1316. doi:10.1016/j.ejca.2010.02.015
Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75-89. doi:10.3322/canjclin.57.2.75
Howell SJ, Searle C, Goode V, et al. The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. Br J Cancer. 2009;101:582-588. doi:10.1038/sj.bjc.6605215
Horst KC, Hancock SL, Ognibene G, et al. Histologic subtypes of breast cancer following radiotherapy for Hodgkin lymphoma. Ann Oncol. 2014;25:848-851. doi:10.1093/annonc/mdu017
Cutuli B, Kanoun S, Tunon De Lara C, et al. Breast cancer occurred after Hodgkin's disease: clinico-pathological features, treatments and outcome: analysis of 214 cases. Crit Rev Oncol Hematol. 2012;81:29-37. doi:10.1016/j.critrevonc.2011.01.005
Castiglioni F, Terenziani M, Carcangiu ML, et al. Radiation effects on development of HER2-positive breast carcinomas. Clin Cancer Res. 2007;13:46-51. doi:10.1158/1078-0432.ccr-06-1490
Wolden SL, Hancock SL, Carlson RW, Goffinet DR, Jeffrey SS, Hoppe RT. Management of breast cancer after Hodgkin's disease. J Clin Oncol. 2000;18:765-772. doi:10.1200/jco.2000.18.4.765
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652-1662. doi:10.1093/jnci/dji372
Bhatia S, Palomares MR, Hageman L, et al. A randomized phase IIb study of low-dose tamoxifen in chest-irradiated cancer survivors at risk for breast cancer. Clin Cancer Res. 2021;27:967-974. doi:10.1158/1078-0432.CCR-20-3609
Sella T, Poorvu PD, Ruddy KJ, et al. Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors. Cancer. 2021;127:2888-2894. doi:10.1002/cncr.33596
DeCensi A, Puntoni M, Guerrieri-Gonzaga A, et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. J Clin Oncol. 2019;37:1629-1637. doi:10.1200/JCO.18.01779
Wassermann J, Gelber SI, Rosenberg SM, et al. Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer. Cancer. 2019;125:3266-3274. doi:10.1002/cncr.32192